{"id":"nct:NCT07102628","kind":"trial","title":"Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes","authors":["Novartis Pharmaceuticals"],"author_count":1,"year":2025,"published":"2025-08-04","venue":"ClinicalTrials.gov","cited_by":null,"doi":null,"arxiv_id":null,"nct_id":"NCT07102628","source_url":"https://clinicaltrials.gov/study/NCT07102628","archive_url":"https://space-kitty.com/papers/nct:NCT07102628","updated":"2026-09-16","pmid":null,"pmcid":null,"openalex_id":null,"pdf_url":null,"abstract":"The purpose of this trial is to learn about the effects of inclisiran in people with serious heart conditions (acute coronary syndromes), when this treatment is started early after hospital admission. To do this, researchers will test the effects of inclisiran compared to placebo, when given with standard treatment.","abstract_license":"ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters","license":"ClinicalTrials.gov terms (attribution, processing date, modifications noted)","is_open_access":true,"retracted":false,"peer_reviewed":null,"categories":["Acute Coronary Syndrome"],"details":{"acronym":"ACS","status":"RECRUITING","phase":"PHASE3","study_type":"INTERVENTIONAL","enrollment":300,"sponsor":"Novartis Pharmaceuticals","conditions":["Acute Coronary Syndrome"],"interventions":["DRUG: Placebo","DRUG: Inclisiran"],"start_date":"2025-10-03","start_date_type":"ACTUAL","primary_completion_date":"2027-02-11","has_results":false,"data_source":"ClinicalTrials.gov","data_processed":"2026-10-29T09:00:05","modifications":"selected fields only; whitespace normalized; brief summary truncated to 2,000 characters"},"provenance":"clinicaltrials","attribution":"Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.","topics":[{"slug":"cardiovascular-innovation","name":"Cardiovascular Therapeutics","domain_slug":"medicine"}],"cited_in_dossiers":[]}